Company Overview
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. The company was incorporated in 2015 and is headquartered in Baltimore, Maryland.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.38.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +62.24% |
| 6 Months: | -32.69% |
| 3 Months: | +201.79% |
| 1 Month: | +44.18% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)69.41 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 41.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NXTC NextCure, Inc. PHARMA | 8.42 | -1.02 | $38.54M | 0.00% | -145.43% | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 1.36M | 1.40M | 1.58M | 22.38M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 11.62M | 27.29M | 8.95M | 9.76M | 10.11M | - |
| Operating Income | -5.01M | -5.30M | -5.82M | -6.82M | -8.96M | -9.70M | 8.21M | -15.80M | -17.40M | -17.23M | -17.95M | -18.51M | -20.77M | -18.13M | -19.24M | -17.07M | -19.16M | -15.62M | -18.30M | -16.49M | -12.49M | - | -11.62M | -27.29M | -8.95M | -9.76M | -10.11M | -15.09M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -10.97M | -26.66M | -8.41M | -9.39M | -9.82M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -10.98M | -26.81M | -8.62M | -9.44M | -9.80M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -5.00M | -5.23M | -5.71M | -6.16M | -8.22M | -8.43M | 9.73M | -14.51M | -16.37M | -16.53M | -17.99M | -17.93M | -20.60M | -17.92M | -18.91M | -16.10M | -17.86M | -14.30M | -17.11M | -15.40M | -11.54M | - | -10.98M | -26.81M | -8.62M | -9.44M | -9.80M | -14.89M |
| Diluted EPS | - | - | - | -4.46 | - | - | 0.33 | - | -0.59 | -0.60 | -0.65 | -0.65 | -0.74 | -0.65 | -0.68 | -0.58 | -0.64 | -0.51 | -0.61 | -6.61 | -4.95 | - | -4.70 | -11.29 | -3.22 | - | -1.87 | -2.80 |
| R&D Expense | 4.21M | 4.43M | 4.89M | 6.51M | 7.64M | 8.66M | 10.58M | 11.13M | 12.74M | 12.39M | 11.95M | 13.60M | 15.02M | 12.82M | 13.53M | 11.65M | 13.45M | 11.01M | 11.40M | 12.42M | 8.77M | - | 7.90M | 24.09M | 6.14M | - | 6.83M | 7.42M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | 6.35M | 22.38M | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | 75.91M | 67.64M | 57.21M | 57.62M |
| Operating Income | -23.20M | -37.48M | -41.23M | -70.77M | -75.91M | -67.64M | -57.21M | -57.62M |
| EBITDA | - | - | - | - | -71.78M | -63.95M | -54.34M | -55.43M |
| Interest Expense | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | -74.73M | -62.72M | -55.65M | -55.84M |
| Tax Provision | - | - | - | - | - | - | - | - |
| Net Income | -22.80M | -33.74M | -36.60M | -69.39M | -74.73M | -62.72M | -55.65M | -55.84M |
| Diluted EPS | - | - | -1.33 | -2.51 | -32.28 | -27.00 | -23.88 | -19.65 |
| R&D Expense | 19.79M | 34.22M | 46.55M | 50.19M | 54.20M | 47.93M | 41.49M | 44.92M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 147.63M | 356.17M | 306.64M | - | 184.16M | 128.04M | 80.86M | 50.18M |
| Current Assets | - | - | - | - | - | 163.98M | 112.72M | 71.81M | 43.75M |
| Cash & Equivalents | - | 135.17M | 34.09M | 32.77M | - | 26.63M | 13.08M | 27.73M | 25.98M |
| Inventory | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - |
| Total Liabilities | - | 32.35M | 34.68M | 12.92M | - | 16.63M | 13.62M | 15.39M | 15.24M |
| Current Liabilities | - | 10.30M | 15.04M | 10.32M | - | 9.13M | 6.88M | 9.57M | 10.57M |
| Long Term Debt | - | 73.00K | 3.33M | 1.81M | - | - | - | - | - |
| Total Debt | - | - | - | - | - | 7.12M | 6.61M | 5.95M | 5.15M |
| Total Equity | -24.41M | -46.94M | 321.48M | 293.72M | - | 167.53M | 114.42M | 65.47M | 34.94M |
| Shares Outstanding | - | - | - | - | - | 2.31M | 2.33M | 2.33M | 3.51M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 7.99M | -35.62M | -44.95M | - | -53.89M | -52.97M | -40.80M | -49.61M |
| Investing Cash Flow | -3.06M | -303.92M | 43.52M | - | 67.98M | 39.27M | 55.31M | 25.56M |
| Financing Cash Flow | 121.42M | 243.04M | -1.42M | - | 200.00K | 154.00K | 144.00K | 22.31M |
| Capital Expenditure | -3.06M | -3.37M | -7.13M | -2.36M | -2.12M | -820.00K | -474.00K | - |
| Free Cash Flow | 4.93M | -38.99M | -52.09M | - | -56.00M | -53.79M | -41.28M | -49.61M |
| Net Change in Cash | - | - | - | - | 14.29M | -13.55M | 14.64M | -1.75M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - |
| Operating Margin % | - | -590.5% | -184.2% | - | - | - | - | - |
| Net Margin % | - | -531.5% | -163.6% | - | - | - | - | - |
| ROE % | 48.6% | -10.5% | -12.5% | - | -44.6% | -54.8% | -85.0% | -159.8% |
| ROCE % | -16.9% | -11.0% | -13.9% | - | -43.4% | -55.8% | -80.2% | -145.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Ikarian Capital, LLC | 7.98% | 288.30K | $1.76M |
| 2 | Adage Capital Partners GP L.L.C. | 7.67% | 277.20K | $1.70M |
| 3 | Sofinnova Investments, Inc. | 6.16% | 222.65K | $1.36M |
| 4 | Renaissance Technologies, LLC | 4.74% | 171.20K | $1.05M |
| 5 | Vanguard Capital Management LLC | 4.34% | 156.84K | $959.87K |
| 6 | Millennium Management Llc | 2.44% | 88.11K | $539.25K |
| 7 | Boothbay Fund Management, LLC | 2.34% | 84.69K | $518.28K |
| 8 | Squadron Capital Management LLC | 1.78% | 64.46K | $394.52K |
| 9 | Verdad Advisers, LP | 1.67% | 60.45K | $369.96K |
| 10 | Pfizer Inc | 1.23% | 44.35K | $271.40K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NXTC
NextCure Provides Business Update and Reports Second Quarter 2026 Financial Results
Announced Proposed Merger with Avere TherapeuticsPreserving Capital in Support of Merger Closing; Continuing Clinical Transition and Legacy Asset Activities BELTSVILLE, Md., Aug. 06, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a…
Fresh off buyout, Akero execs reunite to advance long-acting psoriasis pill
Set to go public via a reverse merger, Avere has licensed from a prolific Chinese drugmaker rights to a potential threat to medicines like Skyrizi and Icotyde.
NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026
55% ORR in gynecologic cancers with 52.9% in ovarian and 66.7% in USC at 12 weeks by best response per RECIST 1.1 within the therapeutic dose range (4.8 – 8.0 mg/kg)Favorable safety and tolerability in heavily pretreated population supports…
NextCure Provides Business Update and Reports First Quarter 2026 Financial Results
SIM0505/CDH6 ADC dose optimization initiated in gynecologic cancersSIM0505 Phase 1 dose escalation study data to be presented at ASCO 2026 LNCB74 Phase 1 dose escalation trial update planned in second half of 2026 BELTSVILLE, Md., May 07, 2…
NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers
Dose optimization will initially be focused on evaluating SIM0505 in patients with platinum-resistant ovarian cancer (PROC) Phase 1 data readout to be presented at ASCO 2026 BELTSVILLE, Md., May 04, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (…
NextCure and Simcere’s SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026
Poster to be presented at the American Society for Clinical Oncology on Monday, June 1, 2026BELTSVILLE, Md., April 21, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discoveri…
NXTC — Frequently Asked Questions
What is the current share price of NextCure, Inc. (NXTC)?
As of 2026-09-19 21:16 PDT, NextCure, Inc. (NXTC) trades at $8.42 on NasdaqGS. Its 52-week range is $1.60 to $14.27.
What is the market capitalisation of NXTC?
NextCure, Inc. (NXTC) has a market capitalisation of $38.54M on NasdaqGS.
What is the P/E ratio of NXTC?
NXTC trades at a trailing price-to-earnings (P/E) ratio of -1.02. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 2.05.
Is NXTC a good stock to buy?
This page provides a data-driven analysis of NextCure, Inc. (NXTC), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.